Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Authors
Keywords
Valsartan, Sitagliptin, Bumetanide, Mefenamic Acid, Biopharmaceutics Classification System
Journal
CLINICAL PHARMACOKINETICS
Volume 53, Issue 1, Pages 17-27
Publisher
Springer Nature
Online
2013-10-08
DOI
10.1007/s40262-013-0104-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
- (2013) Akira Imamura et al. Diabetes Therapy
- Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
- (2012) Sreeneeranj Kasichayanula et al. ADVANCES IN THERAPY
- The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
- (2012) Sreeneeranj Kasichayanula et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Global cardiovascular disease risk assessment in United States adults with diabetes
- (2012) Nathan D Wong et al. Diabetes & Vascular Disease Research
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin
- (2012) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study
- (2012) M. F. B. Braga et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries
- (2012) Michel P Hermans et al. European Journal of Preventive Cardiology
- Structural selectivity of human SGLT inhibitors
- (2011) Charles S. Hummel et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
- (2011) Sreeneeranj Kasichayanula et al. CLINICAL THERAPEUTICS
- Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
- (2011) Glenn F. Carlson et al. Diabetes Therapy
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Diabetes Mellitus Reduces Activity of Human UDP-Glucuronosyltransferase 2B7 in Liver and Kidney Leading to Decreased Formation of Mycophenolic Acid Acyl-Glucuronide Metabolite
- (2010) M. Dostalek et al. DRUG METABOLISM AND DISPOSITION
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Glucose Control by the Kidney: An Emerging Target in Diabetes
- (2009) Olivera Marsenic AMERICAN JOURNAL OF KIDNEY DISEASES
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now